BIOMIGA

Fuente: Zenodo
Guardado en:
Detalles Bibliográficos
Autores principales: Martinelli, Daniele, Tassorelli, Cristina, Pozo-Rosich, Patricia, May, Arne
Formato: Recurso digital
Publicado: Zenodo 2025
Materias:
Acceso en línea:
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
_version_ 1866901168430514176
author Martinelli, Daniele
Tassorelli, Cristina
Pozo-Rosich, Patricia
May, Arne
author_facet Martinelli, Daniele
Tassorelli, Cristina
Pozo-Rosich, Patricia
May, Arne
contents <p>Migraine is a common neurological disorder and a major source of disability. Though curable in principle, migraine generally improves poorly with available treatments, due to their limited efficacy and scarce tolerability. In 2018, monoclonal antibodies (mABs) against calcitonin gene-related peptide (CGRP) receptor have been approved. These mABs are the first specific preventive treatment for migraine ever developed. They are highly effective in a subgroup of patients, well tolerated, but costly. The main objective of this project is the identification of predictive biomarkers of response to CGRP-targeted mAbs in patients with migraine. In this project, we used a hypothesis-driven, multidisciplinary approach that combines fundamental research in a validated animal model of migraine with a variegated and integrated <span>'</span>omics<span>'</span> approach on a carefully characterized population of migraine sufferers.</p> <p> </p> <p>In the shared folder it is possible to find all the anonymised raw data regarding:</p> <p>- clinical, psychological and disability measures of the patients before and after the use of erenumab</p> <p>- MRI scan (fRMI and T13D and perfusion map)</p> <p>- epigenetics analysis: level of methylation of the cpg island of relevant gene associated with migraine and CGRP</p> <p>- biochemical evaluation of circulating inflammatory peptide and gene expression level</p> <p>- genetic profiling</p>
format Recurso digital
id zenodo_https___doi_org_10_5281_zenodo_15007020
institution Zenodo
language
publishDate 2025
publisher Zenodo
record_format zenodo
spellingShingle BIOMIGA
Martinelli, Daniele
Tassorelli, Cristina
Pozo-Rosich, Patricia
May, Arne
Imaging techniques
Pharmacology
Behavioural methodologies
(epi)genetic approaches
Clinical trial
omics approaches
Animal studies
Migraine
calcitonin gene-related peptide
monoclonal antibodies
<p>Migraine is a common neurological disorder and a major source of disability. Though curable in principle, migraine generally improves poorly with available treatments, due to their limited efficacy and scarce tolerability. In 2018, monoclonal antibodies (mABs) against calcitonin gene-related peptide (CGRP) receptor have been approved. These mABs are the first specific preventive treatment for migraine ever developed. They are highly effective in a subgroup of patients, well tolerated, but costly. The main objective of this project is the identification of predictive biomarkers of response to CGRP-targeted mAbs in patients with migraine. In this project, we used a hypothesis-driven, multidisciplinary approach that combines fundamental research in a validated animal model of migraine with a variegated and integrated <span>'</span>omics<span>'</span> approach on a carefully characterized population of migraine sufferers.</p> <p> </p> <p>In the shared folder it is possible to find all the anonymised raw data regarding:</p> <p>- clinical, psychological and disability measures of the patients before and after the use of erenumab</p> <p>- MRI scan (fRMI and T13D and perfusion map)</p> <p>- epigenetics analysis: level of methylation of the cpg island of relevant gene associated with migraine and CGRP</p> <p>- biochemical evaluation of circulating inflammatory peptide and gene expression level</p> <p>- genetic profiling</p>
title BIOMIGA
topic Imaging techniques
Pharmacology
Behavioural methodologies
(epi)genetic approaches
Clinical trial
omics approaches
Animal studies
Migraine
calcitonin gene-related peptide
monoclonal antibodies
url https://doi.org/10.5281/zenodo.15007020